secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005006
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics reports preliminary Q4 revenue $22.1M, FY2024 $74.5M; issues 2025 guidance with 12-19% growth
--------------------------------------------------------------------------------

- Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).
- Closed acquisition of Greenbrook TMS Dec 9, 2024; expects over $22M annualized cost synergies.
- FY2025 revenue guidance $145M-$155M, pro forma growth 12-19%; gross margin ~55%.
- Expects cash flow breakeven in Q3 2025; reduced cash burn in H1 2025.
- Launched Better Me Provider program with over 350 sites; FDA clearance for adolescent MDD expanded TAM by 35%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/0001193125-25-005006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/d925718d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer